Sponsored by
This is the final results of the Optune trial. Survival rates were 43 percent versus 31 percent at two years; 26 percent versus 16 percent at three years, and 13 percent versus 5 percent at five years. These results are impressive. The survival advantage has improved since the last report as there are now more 5 year survivors. All subgroups of patients had a benefit - methylated or unmethylated, young or old, gross total resection and biopsy only. They also clarified their position of letting every patient who wants to use it get it regardless of ability to pay.